Hematopoietic stem cell transplantation in children with thalassemia: Brazilian Society of Bone Marrow Transplantation Consensus
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e292Keywords:
Thalassemia, Hematopoietic Stem Cell Transplantation, Hematology, PediatricsAbstract
Allogeneic hematopoietic cell transplantation (HCT) represents a critical therapeutic option for patients with transfusiondependent thalassemia (TDT), with thalassemia-free survival rates exceeding 90% in cases involving HLA-matched sibling donors. Due to the limited availability of matched donors, alternative sources such as HLA-matched unrelated donors, haploidentical donors, and umbilical cord blood have broadened HCT eligibility. Despite its potential for cure, HCT involves risks like graft-versus-host disease, graft rejection, and transplant-related mortality. Recent improvements in conditioning regimens have enhanced patient outcomes and quality of life. Factors affecting HCT success in TDT include recipient age, disease complications, effective chelation therapy, Pesaro score, and donor compatibility. This article aimed to update the Brazilian consensus established by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, incorporating the latest advances in treating and managing TDT patients undergoing transplantation.
References
1. Oikonomopoulou C, Goussetis E. HSCT remains the only cure for patients with transfusion-dependent thalassemia until gene therapy strategies are proven to be safe. Bone Marrow Transplant. 2021;56(12):2882–8. https://doi.org/10.1038/s41409-021-01461-0 DOI: https://doi.org/10.1038/s41409-021-01461-0
2. Strocchio L, Locatelli F. Hematopoietic stem cell transplantation in thalassemia. Hematol Oncol Clin North Am. 2018;32(2):317–28. https://doi.org/10.1016/j.hoc.2017.11.011 DOI: https://doi.org/10.1016/j.hoc.2017.11.011
3. Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A, Pagliara D, Contoli B, Pinto RM, Caocci G, Mastronuzzi A, La Nasa G, Locatelli F. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012;120(2):473–6. https://doi.org/10.1182/blood-2012-04-423822 DOI: https://doi.org/10.1182/blood-2012-04-423822
4. Algeri M, Lodi M, Locatelli F. Hematopoietic stem cell transplantation in thalassemia. Hematol Oncol Clin North Am. 2023;37(2):413–32. https://doi.org/10.1016/j.hoc.2022.12.009 DOI: https://doi.org/10.1016/j.hoc.2022.12.009
5. Darrigo Junior LG, Mello Costa TC, Vieira AK, Albino CD, Navarro Barros GM, Garcia JL, Fortunato LR, Santos FLS, Fonseca G, Guerino-Cunha RL, Santis GC, Simões BP. Hematopoietic stem cell transplantation in children with hemoglobinopathies: Brazilian Society of Bone Marrow Transplantation Consensus. J Bone Marrow Transplant Cell Ther. 2021;2(4):132. https://doi.org/10.46765/2675-374X.2021v2n4p132 DOI: https://doi.org/10.46765/2675-374X.2021v2n4p132
6. Lucarelli G, Galimberti M, Giardini C, Polchi P, Angelucci E, Baronciani D, Erer B, Gaziev D. Bone marrow transplantation in thalassemia: the experience of Pesaro. Ann N Y Acad Sci. 1998;850:270–5. https://doi.org/10.1111/j.1749-6632.1998.tb10483.x DOI: https://doi.org/10.1111/j.1749-6632.1998.tb10483.x
7. Mathews V, George B, Deotare U, Lakshmi KM, Viswabandya A, Daniel D, Chandy M, Srivastava A. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with β thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(8):889–94. https://doi.org/10.1016/j.bbmt.2007.05.004 DOI: https://doi.org/10.1016/j.bbmt.2007.05.004
8. Sabloff M, Chandy M, Wang Z, Logan BR, Ghavamzadeh A, Li CK, Irfan SM, Bredeson CN, Cowan MJ, Gale RP, Hale GA, Horan J, Hongeng S, Eapen M, Walters MC. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2011;117(5):1745–50. https://doi.org/10.1182/blood-2010-09-306829 DOI: https://doi.org/10.1182/blood-2010-09-306829
9. Thomas ED, Buckner CD, Sanders JE, Papayannopoulou T, Borgna-Pignatti C, De Stefano P, Sullivan KM, Clift RA, Storb R. Marrow transplantation for thalassaemia. The Lancet. 1982;2(8292):227–9. https://doi.org/10.1016/s0140-6736(82)90319-1 DOI: https://doi.org/10.1016/S0140-6736(82)90319-1
10. Li C, Mathews V, Kim S, George B, Hebert K, Jiang H, Li C, Zhu Y, Keesler DA, Boelens JJ, Dvorak CC, Agarwal R, Auletta JJ, Goyal RK, Hanna R, Kasow K, Shenoy S, Smith AR, Walters MC, Eapen M. Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Adv. 2019;3(17):2562–70. https://doi.org/10.1182/bloodadvances.2019000291 DOI: https://doi.org/10.1182/bloodadvances.2019000291
11. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E, Baronciani D, Andreani M, Manna M, Nesci S, Lucarelli B, Clift RA, Lucarelli G. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104(4):1201–3. https://doi.org/10.1182/blood-2003-08-2800 DOI: https://doi.org/10.1182/blood-2003-08-2800
12. Gaziev J, Isgrò A, Sodani P, Marziali M, Paciaroni K, Gallucci C, De Angelis G, Andreani M, Testi M, Alfieri C, Ribersani M, Galluccio T, Battarra MR, Morrone A, Lucarelli G. Optimal outcomes in young class 3 patients with thalassemia undergoing HLA-identical sibling bone marrow transplantation. Transplantation. 2016;100(4):925–32. https://doi.org/10.1097/tp.0000000000000928 DOI: https://doi.org/10.1097/TP.0000000000000928
13. Anurathapan U, Pakakasama S, Mekjaruskul P, Sirachainan N, Songdej D, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Pongtanakul B, Rujkijyanont P, Meekaewkunchorn A, Sruamsiri R, Ungkanont A, Issaragrisil S, Andersson BS, Hongeng S. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biol Blood Marrow Transplant. 2014;20(12):2066–71. https://doi.org/10.1016/j.bbmt.2014.07.016 DOI: https://doi.org/10.1016/j.bbmt.2014.07.016
14. Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK, Bernaudin F, Vermylen C, Dalle JH, Stein J, Wynn R, Cordonnier C, Pinto F, Angelucci E, Socié G, Gluckman E, Walters MC, Rocha V; Eurocord and European Blood and Marrow Transplantation (EBMT) group. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013;122(6):1072–8. https://doi.org/10.1182/blood-2013-03-489112 DOI: https://doi.org/10.1182/blood-2013-03-489112
15. Bernaudin F, Dalle JH, Bories D, de Latour RP, Robin M, Bertrand Y, Pondarre C, Vannier JP, Neven B, Kuentz M, Maury S, Lutz P, Paillard C, Yakouben K, Thuret I, Galambrun C, Dhedin N, Jubert C, Rohrlich P, Bay JO, Suarez F, Raus N, Vernant JP, Gluckman E, Poirot C, Socié G; Société Française de Greffe de Moelle et de Thérapie Cellulaire. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched sibling transplantation in France. Haematologica. 2020;105(1):91–101. https://doi.org/10.3324/haematol.2018.213207 DOI: https://doi.org/10.3324/haematol.2018.213207
16. McPherson ME, Hutcherson D, Olson E, Haight AE, Horan J, Chiang KY. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant. 2011;46(1):27–33. https://doi.org/10.1038/bmt.2010.60 DOI: https://doi.org/10.1038/bmt.2010.60
17. Swaminathan VV, Uppuluri R, Patel S, Ravichandran N, Ramanan KM, Vaidhyanathan L, Ramakrishnan B, Jayakumar I, Raj R. Matched family versus alternative donor hematopoietic stem cell transplantation for patients with thalassemia major: experience from a tertiary referral center in South India. Biol Blood Marrow Transplant. 2020;26(7):1326–31. https://doi.org/10.1016/j.bbmt.2020.03.016 DOI: https://doi.org/10.1016/j.bbmt.2020.03.016
18. Mulas O, Mola B, Caocci G, La Nasa G. Conditioning regimens in patients with β-thalassemia who underwent hematopoietic stem cell transplantation: a scoping review. J Clin Med. 2022;11(4):907. https://doi.org/10.3390/jcm11040907 DOI: https://doi.org/10.3390/jcm11040907
19. Locatelli F, Merli P, Strocchio L. Transplantation for thalassemia major: alternative donors. Curr Opin Hematol. 2016;23(6):515–23. https://doi.org/10.1097/moh.0000000000000280 DOI: https://doi.org/10.1097/MOH.0000000000000280
20. Xiao H, Huang Q, Lai Y, Liu R. Haploidentical hematopoietic stem cell transplantation in pediatric transfusiondependent thalassemia: a systematic review and meta-analysis. Transplant Cell Ther. 2025;31(2):101. e1–101.e12. https://doi.org/10.1016/j.jtct.2024.12.001 DOI: https://doi.org/10.1016/j.jtct.2024.12.001
21. Anurathapan U, Pakakasama S, Songdej D, Pongphitcha P, Chuansumrit A, Andersson BS, Hongeng S. Haploidentical hematopoietic stem cell transplantation in thalassemia. Hemoglobin. 2022;46(1):2–6. https://doi.org/10.1080/03630269.2022.2059671 DOI: https://doi.org/10.1080/03630269.2022.2059671
22. Anurathapan U, Hongeng S, Pakakasama S, Songdej D, Sirachainan N, Pongphitcha P, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Rujkijyanont P, Meekaewkunchorn A, Lektrakul Y, Iamsirirak P, Surapolchai P, Sirireung S, Sruamsiri R, Wahidiyat PA, Andersson BS. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen. Biol Blood Marrow Transplant. 2020;26(6):1106–12. https://doi.org/10.1016/j.bbmt.2020.01.002 DOI: https://doi.org/10.1016/j.bbmt.2020.01.002
23. Mayuranathan T, Newby GA, Feng R, Yao Y, Mayberry KD, Lazzarotto CR, Li Y, Levine RM, Nimmagadda N, Dempsey E, Kang G, Porter SN, Doerfler PA, Zhang J, Jang Y, Chen J, Bell HW, Crossley M, Bhoopalan SV, Sharma A, Tisdale JF, Pruett-Miller SM, Cheng Y, Tsai SQ, Liu DR, Weiss MJ, Yen JS. Potent and uniform fetal hemoglobin induction via base editing. Nat Genet. 2023;55(7):1210–20. https://doi.org/10.1038/s41588-023-01434-7 DOI: https://doi.org/10.1038/s41588-023-01434-7
24. Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, Sauer MG, Thuret I, Lal A, Algeri M, Schneiderman J, Olson TS, Carpenter B, Amrolia PJ, Anurathapan U, Schambach A, Chabannon C, Schmidt M, Labik I, Elliot H, Guo R, Asmal M, Colvin RA, Walters MC. Betibeglogene autotemcel gene therapy for non–β0 /β0 genotype β-thalassemia. N Engl J Med. 2022;386(5):415–27. https://doi.org/10.1056/nejmoa2113206 DOI: https://doi.org/10.1056/NEJMoa2113206
25. Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW, Kattamis A, Kernytsky A, Lekstrom-Himes J, Li AM, Locatelli F, Mapara MY, de Montalembert M, Rondelli D, Sharma A, Sheth S, Soni S, Steinberg MH, Wall D, Yen A, Corbacioglu S. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–60. https://doi.org/10.1056/nejmoa2031054 DOI: https://doi.org/10.1056/NEJMoa2031054
26. Goyal S, Tisdale J, Schmidt M, Kanter J, Jaroscak J, Whitney D, Bitter H, Gregory PD, Parsons G, Foos M, Yeri A, Gioia M, Voytek SB, Miller A, Lynch J, Colvin RA, Bonner M. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med. 2022;386(2):138–47. https://doi.org/10.1056/nejmoa2109167 DOI: https://doi.org/10.1056/NEJMoa2109167
27. Andreani M, Testi M, Lucarelli G. Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance. Tissue Antigens. 2014;83(3):137–46. https://doi.org/10.1111/tan.12313 DOI: https://doi.org/10.1111/tan.12313
28. Chen H, Li XY, Zhan LP, Fang JP, Huang K, Li Y, Weng WJ, Xu LH, Xu HG, Zhou DH. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion‐dependent pediatric thalassemia patients. Pediatr Transplant. 2020;24(8):e13876. https://doi.org/10.1111/petr.13876 DOI: https://doi.org/10.1111/petr.13876
29. Mehta P, Singh A, Halder R, Verma M, Agrawal N, Ahmed R, Bhurani D. Immunosuppression boost with mycophenolate mofetil for mixed chimerism in thalassemia transplants. Transplant Cell Ther. 2023;29(2):122.e1–122.e6. https://doi.org/10.1016/j.jtct.2022.11.008 DOI: https://doi.org/10.1016/j.jtct.2022.11.008
30. Angelucci E. How I manage iron overload in the hematopoietic cell transplantation setting. Blood. 2025;145(4):372–82. https://doi.org/10.1182/blood.2023022500 DOI: https://doi.org/10.1182/blood.2023022500
31. Wang C, Zhao M, Liu Q, Yang Y, Li Y, Nie Y, Gao S, Li W. Impact of iron overload in hematopoietic stem cell transplantation. Transpl Immunol. 2023;78:101820. https://doi.org/10.1016/j.trim.2023.101820 DOI: https://doi.org/10.1016/j.trim.2023.101820
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Luiz Guilherme Darrigo Junior, Ana Karine Vieira, Cilmara Kuwahara, Roseane Vasconcelos Gouveia, Paulo Klinger, Alexandre de Albuquerque Antunes, Julia Lopes Garcia
This work is licensed under a Creative Commons Attribution 4.0 International License.
